This is the user sandbox of UnknownCoder00. A user sandbox is a subpage of the user's user page. It serves as a testing spot and page development space for the user and is not an encyclopedia article. Create or edit your own sandbox here.

Other sandboxes: Main sandbox | Template sandbox

Finished writing a draft article? Are you ready to request review of it by an experienced editor for possible inclusion in Wikipedia? Submit your draft for review!

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Inc.
	File:Amphastar Pharmaceuticals Inc. Logo.svg
Company type	Public
Traded as	Nasdaq: AMPH;
Industry	Biotechnology
Headquarters	Rancho Cucamonga, California, U.S.
Key people	Yongfeng "Jack" Zhang; (Chairman, Founder, and CEO)
Products	enoxaparin sodium, medroxyprogesterone acetage, naloxone, phytonadione, Primatene Mist, cosyntropin, hyaluronidase, etc.
Revenue	US$294.66 million (2018)
Operating income	US$115.60 million
Net income	US$5.73 million (2018)
Total assets	US$513.56 million (2018)
Total equity	US$332.43 million (2018)
Number of employees	2,078 (December 2018)
Website	www.amphastar.com

From Wikipedia, the free encyclopedia

Amphastar Pharmaceuticals is a publicly traded American specialty pharmaceutical company. It was incorporated in May 2004 in Rancho Cucamonga, California and primarily develops, manufactures, and sells inhalation, intranasal, and injectable products.

History

Timeline

Acquisition Timeline

Products

References

External Links

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.